TY - JOUR
T1 - Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib
T2 - A randomized trial
AU - Brixen, Kim
AU - Chapurlat, Roland
AU - Cheung, Angela M.
AU - Keaveny, Tony M.
AU - Fuerst, Thomas
AU - Engelke, Klaus
AU - Recker, Robert
AU - Dardzinski, Bernard
AU - Verbruggen, Nadia
AU - Ather, Shabana
AU - Rosenberg, Elizabeth
AU - De Papp, Anne E.
PY - 2013/2/1
Y1 - 2013/2/1
N2 - Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P
AB - Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD)in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P
UR - http://www.scopus.com/inward/record.url?scp=84873684246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873684246&partnerID=8YFLogxK
U2 - 10.1210/jc.2012-2972
DO - 10.1210/jc.2012-2972
M3 - Article
C2 - 23337728
AN - SCOPUS:84873684246
VL - 98
SP - 571
EP - 580
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 2
ER -